Table 3 : Clinical phase II studies with O6-BG and O6-BTG.


Drug combination Cancer type Results Reference

Clinical phase II studies with O6-BG

TMZ+O6-BG Glioblastoma multiforme
Anaplastic glioma
3% RR
16% RR
[57]
TMZ+O6-BG Progressive high-grade glioma
Brainstem glioma
4% RR
0% RR
[58]
BCNU+O6-BG Multiple myeloma 27% RR [59]
BCNU+O6-BG Recurrent or progressive glioma 0% RR [60]
BCNU+O6-BG Advanced soft tissue sarcoma 0% RR [61]
BCNU+O6-BG Advanced melanoma 5% RR [62]

Clinical phase II studies with O6-BTG

TMZ alone
TMZ+O6-BTG
Metastatic cutaneous melanoma 13.5% RR
17.3% RR
[64]
TMZ alone
TMZ+O6-BTG
Metastatic colorectal carcinoma 0% RR
0% RR
[65]
TMZ alone
TMZ+O6-BTG
Metastatic melanoma Partial MGMT depletion
Complete MGMT depletion
[66]

Peters et al.Oncology Discovery  2014 2:3DOI : 10.7243/2052-6199-2-3